Topics

Medulloblastoma | Treatment | Immunotherapy | Overview

Home > Publications > Topics > Medulloblastoma > Treatment > Immunotherapy > Overview

2026

Abu-Arja MH, Stuckert A, Ghebrelul RT, Chintagumpala M, Taylor MD, Ahmed N.
Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma.
J Neurooncol. 2026 Mar 11;177(1):39. doi: 10.1007/s11060-026-05437-2. PMID: 41811637˰ ˍ

Fontão P, Viana-Pereira M, Pinto-Ribeiro F, Junqueira T, Reis RM.
Outcomes of immunotherapy in medulloblastoma: a systematic review.
Oncologist. 2026 Apr 6;31(6):oyag109. doi: 10.1093/oncolo/oyag109. PMID: 41950392. ˍ

Fontão P, Viana-Pereira M, Pinto-Ribeiro F, Junqueira T, Reis RM.
Outcomes of immunotherapy in medulloblastoma: a systematic review.
Oncologist. 2026 May 8;31(6):oyag109. doi: 10.1093/oncolo/oyag109. PMID: 41950392. ˍ

Chatterjee S, Kumar P, Kumar AS, Lei PJ, Datta M, Zhao Y, Ho WW, Talele NP, Andersson P, Duquette M, Kitahara S, Blanc L, Wong SJ, Kwanten WJ, Ebb DH, Yock TI, Dartois V, Fukumura D, Duda DG, Xu L, Kim HJ, Jain RK.
Targeting Tumor-derived Sphingosine Kinase 2 Unleashes Antitumor Immunity and Improves Survival of Mice with Group 3 Medulloblastoma.
bioRxiv [Preprint]. 2026 Aug 13:2026.08.12.744521. doi: 10.64898/2026.08.12.744521. PMID: 42845663. ˍ